Breast cancer metastasis: markers and models
The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Breast cancer starts as a local disease, but it can metastasize to the lymph nodes and distant organs. At primary diagnosis, prognostic markers are used to assess whether the transition to systemic disease is likely to have occurred. The prevailing model of metastasis reflects this view--it suggests that metastatic capacity is a late, acquired event in tumorigenesis. Others have proposed the idea that breast cancer is intrinsically a systemic disease. New molecular technologies, such as DNA microarrays, support the idea that metastatic capacity might be an inherent feature of breast tumours. These data have important implications for prognosis prediction and our understanding of metastasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immune cells were shown to both enhance and inhibit malignant cells proliferation, migration, and metastasis [125-128].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [125]
In the citing paper
“Chemical gradients play an important role in tumor cell invasion of metastatic cancer [195,196] as it significantly directs the migration and differentiation of tumor cells.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [196]
In the citing paper
“Metastasis is the leading cause of death from breast cancer1, 37-39.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [1]
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“ERBB2 is overexpressed due to gene amplification in 15–30% of human breast cancer”
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Research works printed but not linked: 2
- Fidler, I. J. Metastasis: quantitative analysis of distribution and fate of tumour embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J. Natl Cancer Inst. 45, 773–782 (1970).
- Leighton, J. Inherent malignancy of cancer cells possibly limited by genetically differing cells in the same tumour. Acta Cytol. 9, 138–140 (1965).
Cited by
Items 401–500 of 1,003
A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer
Zhang, T., Li, J., He, Y., Yang, F., Hao, Y., Jin, W., Wu, J., Sun, Z., Li, Y., Chen, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06179-0 · Cited by 82
FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth
Tancioni, I., Miller, N. L., Uryu, S., Lawson, C., Jean, C., Chen, X. L., Kleinschmidt, E. G., & Schlaepfer, D. D. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0551-x · Cited by 71
Integrin‐linked kinase regulates E‐cadherin expression through PARP‐1
McPhee, T. R., McDonald, P. C., Oloumi, A., & Dedhar, S. (2008) · Developmental Dynamics · doi:10.1002/dvdy.21685 · Cited by 80
Molecular Imaging of Tumor-Infiltrating Macrophages in a Preclinical Mouse Model of Breast Cancer
Sun, X., Gao, D., Gao, L., Zhang, C., Yu, X., Jia, B., Wang, F., & Liu, Z. (2015) · Theranostics · doi:10.7150/thno.11546 · Cited by 77
Fouani, L., Menezes, S. V., Paulson, M., Richardson, D. R., & Kovačević, Ž. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.001 · Cited by 83
Cook, M., Liang, Y., Besch-Williford, C. L., & Hyder, S. M. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s124860 · Cited by 79
“3, 29 Many existing treatments for TNBC are In the present studies, LU significantly inhibited metastasis of both MDA-MB-435 and MDA-231 (4175) LM2 TNBC cells with no observed toxicity.”
Jalalian, S. H., Ramezani, M., Abnous, K., & Taghdisi, S. M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.12.023 · Cited by 76
From latency to overt bone metastasis in breast cancer: potential for treatment and prevention
Salvador, F., Lope, A. L., & Gomis, R. R. (2019) · The Journal of Pathology · doi:10.1002/path.5292 · Cited by 76
A combined approach to data mining of textual and structured data to identify cancer-related targets
Pospíšil, P., Iyer, L. K., Adelstein, S. J., & Kassis, A. I. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-354 · Cited by 73
“From this final dataset, we have identified several hydrolases, among them peptidases (matrix metalloproteinases and kallikreins) and phosphatases (see Figure 3 for IPA subnetwork) and several known cancer progression markers, matrix metalloproteinases (MMP1, MMP2, MMP3, MMP7, MMP9) [35] and coagulation factors II, II…”
BackgroundCrawford, N. P. S., Walker, R. C., Lukes, L., Officewala, J. S., Williams, R. W., & Hunter, K. W. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9146-6 · Cited by 89
V-ATPase Inhibition Regulates Anoikis Resistance and Metastasis of Cancer Cells
Schempp, C. M., von Schwarzenberg, K., Schreiner, L., Kubisch, R., Müller, R., Wagner, E., & Vollmar, A. M. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0484 · Cited by 80
Snyder, K., Hughes, M. R., Hedberg, B. J., Brandon, J., Hernaez, D. C., Bergqvist, P. J., Cruz, F., Po, K., Graves, M. L., Turvey, M. E., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0562-7 · Cited by 73
Stillfried, G. E., Saunders, D. N., & Ranson, M. (2007) · Breast Cancer Research · doi:10.1186/bcr1647 · Cited by 73
The multifaceted role of extracellular vesicles in metastasis: Priming the soil for seeding
dos Anjos Pultz, B., Andrés Cordero da Luz, F., Socorro Faria, S., Peixoto Ferreira de Souza, L., Cristina Brígido Tavares, P., Alonso Goulart, V., Fontes, W., Ricardo Goulart, L., & José Barbosa Silva, M. (2017) · International Journal of Cancer · doi:10.1002/ijc.30595 · Cited by 74
Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models
Zeng, A., Yu, Y., Yao, Y.-Q., Yang, F.-F., Liao, M., Song, L.-J., Li, Y.-L., Yu, Y., Li, Y., Zeng, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23376 · Cited by 73
Fibronectin-targeted dual-acting micelles for combination therapy of metastatic breast cancer
Gong, Z., Chen, M., Ren, Q., Yue, X., & Dai, Z. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0104-3 · Cited by 74
Prostate cancer stem cells and their potential roles in metastasis
Li, H., & Tang, D. G. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21806 · Cited by 72
Hong, H., Zhang, Y., Severin, G. W., Yang, Y., Engle, J. W., Niu, G., Nickles, R. J., Chen, X. S., Leigh, B. R., Barnhart, T. E., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300277f · Cited by 72
Bio‐Nano‐Magnetic Materials for Localized Mechanochemical Stimulation of Cell Growth and Death
Kilinc, D., Dennis, C. L., & Lee, G. U. (2016) · Advanced Materials · doi:10.1002/adma.201504845 · Cited by 72
Stenström, J., Hedenfalk, I. A., & Hagerling, C. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01403-0 · Cited by 77
CD44 and HCELL: Preventing hematogenous metastasis at step 1
Jacobs, P. P., & Sackstein, R. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.07.039 · Cited by 77
miR-181b promotes chemoresistance in breast cancer by regulating Bim expression
Zheng, Y., Lv, X., Wang, X., Wang, B., Shao, X., Huang, Y., Shi, L., Chen, Z., Huang, J., & Huang, P. C. (2015) · Oncology Reports · doi:10.3892/or.2015.4417 · Cited by 73
MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer
Luo, L.-J., Yang, F., Ding, J.-J., Yan, D., Wang, D., Yang, S., Ding, L., Li, J., Chen, D., Ma, R., et al. (2016) · Gene · doi:10.1016/j.gene.2016.08.057 · Cited by 72
“However, the molecular mechanism of TNBC metastasis is still poorly understood (Weigelt et al., 2005).”
Manka, D., Spicer, Z., & Millhorn, D. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3091 · Cited by 69
“Our finding that Bnip-3 silencing induces or increases metastatic growth in the lung, liver, and bone, which are the three most common metastasis sites of breast cancer at autopsy (21), support the relevance of this study.”
MicroRNA-193a inhibits breast cancer proliferation and metastasis by downregulating WT1
Xie, F., Hosany, S., Zhong, S., Jiang, Y., Zhang, F., Lin, L., Wang, X., Gao, S., & Hu, X. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185565 · Cited by 75
GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner
Lin, F., Xie, Y.-J., Zhang, X.-K., Huang, T.-J., Xu, H.-F., Mei, Y., Hu, L., Hu, H., Lin, S.-T., Luo, F., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1157-4 · Cited by 72
Long Non-coding RNA DANCR as an Emerging Therapeutic Target in Human Cancers
Jin, S.-J., Jin, M., Xia, B.-R., & Jin, W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01225 · Cited by 73
Mo, D., He, F., Zheng, J., Chen, H., Tang, L. P., & Yan, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656078 · Cited by 77
Ye, T., Wei, X., Yin, T., Xia, Y., Li, D., Shao, B., Song, X., He, S., Luo, M., Gao, X., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2829-y · Cited by 70
“Meanwhile, breast cancer is characterized by a variety of metastatic patterns, which involve lymph nodes, bone, brain, liver and lung; metastasis induced by breast cancer poses a predominant threat to cancer-related mortality in women [2–5].”
BackgroundZhang, M., Chiu, L. C. M., Cheung, P. C. K., & Ooi, V. E. C. (2006) · Oncology Reports · doi:10.3892/or.15.3.637 · Cited by 70
Gupta, P., Adkins, C. E., Lockman, P. R., & Srivastava, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067278 · Cited by 70
Jiang, T., Chen, L., Huang, Y., Wang, J., Xu, M., Zhou, S., Gu, X. Q., Chen, Y., Liang, K., Pei, Y., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b00495 · Cited by 69
Identification of genomic signatures in circulating tumor cells from breast cancer
Kanwar, N., Hu, P., Bedard, P., Clemons, M., McCready, D., & Done, S. J. (2015) · International Journal of Cancer · doi:10.1002/ijc.29399 · Cited by 67
Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion
Wang, H., Stoecklein, N. H., Lin, P. P., & Gires, O. (2016) · Oncotarget · doi:10.18632/oncotarget.12242 · Cited by 70
Pathologic differential diagnosis of metastatic carcinoma in the liver
Park, J. H., & Kim, J. H. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2018.0067 · Cited by 69
The Role of PPARγ Ligands in Breast Cancer: From Basic Research to Clinical Studies
Augimeri, G., Giordano, C., Gelsomino, L., Plastina, P., Barone, I., Catalano, S., Andò, S., & Bonofiglio, D. (2020) · Cancers · doi:10.3390/cancers12092623 · Cited by 71
FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis
Song, Y., Zeng, S., Zheng, G., Chen, D., Li, P., Yang, M., Luo, K., Yin, J., Gu, Y., Zhang, Z., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01562-y · Cited by 71
The Association of Serum IL-33 and sST2 with Breast Cancer
Yang, Z., Ling, D.-Y., Xie, Y., Wu, W., Li, J.-R., Jiang, J. F., Zheng, J.-L., Fan, Y., & Zhang, Y. (2015) · Disease Markers · doi:10.1155/2015/516895 · Cited by 68
Park, S. Y., KIM, J.-H., Lee, Y. J., Lee, S. J., & KIM, Y. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1695 · Cited by 70
Ogba, N., Manning, N. G., Bliesner, B., Ambler, S. K., Haughian, J. M., Pinto, M. P., Jedlicka, P., Joensuu, K. M., Heikkilä, P., & Horwitz, K. B. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0489-4 · Cited by 74
“The same sites are colonized in patients regardless of breast tumor subtype [46].”
Weidle, U. H., Niewöhner, J., & Tiefenthaler, G. (2015) · PubMed · Cited by 78
Cai, X., Liu, X., Liao, L., Bandla, A., Ling, J. M., Liu, Y., Thakor, N. V., Bazan, G. C., & Liu, B. (2016) · Small · doi:10.1002/smll.201600697 · Cited by 67
p62/SQSTM1 interacts with vimentin to enhance breast cancer metastasis
Li, S.-S., Xu, L.-Z., Zhou, W., Yao, S. J., Wang, C.-L., Xia, J.-L., Wang, H.-F., Muhammad, K. I., Xue, X.-Y., Dong, L., et al. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx099 · Cited by 69
Raman spectroscopy of breast cancer
Lazaro‐Pacheco, D., Shaaban, A. M., Rehman, S., & Rehman, I. U. (2019) · Applied Spectroscopy Reviews · doi:10.1080/05704928.2019.1601105 · Cited by 71
Kubisch, R., Fröhlich, T., Arnold, G. J., Schreiner, L., von Schwarzenberg, K., Roidl, A., Vollmar, A. M., & Wagner, E. (2013) · International Journal of Cancer · doi:10.1002/ijc.28562 · Cited by 74
Epigenetic Changes of CXCR4 and Its Ligand CXCL12 as Prognostic Factors for Sporadic Breast Cancer
Ramos, E. A. D. S., Grochoski, M., Braun-Prado, K., Seniski, G. G., Cavalli, I. J., Ribeiro, E. M. S. F., Camargo, A. A., Costa, F. F., & Klassen, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029461 · Cited by 67
Fu, X., Goglia, L., Sanchez, A. M., Flamini, M. I., Giretti, M. S., Tosi, V., Genazzani, A. R., & Simoncini, T. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0258 · Cited by 74
“Local and distant breast cancer progression is the main reason for morbidity and mortality (Weigelt et al. 2005).”
BackgroundKhodadadi‐Jamayran, A., Oksuz, B. A., Afanasyeva, Y., Heguy, A., Thompson, M., Ray, K., Giró‐Perafita, A., Sánchez, I., Wu, X., Tripathy, D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24403 · Cited by 67
Chen, J., Li, N., Liu, B., Ling, J., Yang, W., Pang, X., & Li, T. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117469 · Cited by 68
Zhang, J., Wang, G., Ren, J., Yang, Z., Li, D., Cui, Y., & Yang, X. (2022) · European Radiology · doi:10.1007/s00330-021-08504-6 · Cited by 66
Microfluidics-based approaches for separation and analysis of circulating tumor cells
Yin, J., Deng, J., Du, C., Zhang, W., & Jiang, X. (2019) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2019.07.018 · Cited by 66
Podocalyxin in Normal Tissue and Epithelial Cancer
Tran, N. L., Wang, Y., & Nie, G. (2021) · Cancers · doi:10.3390/cancers13122863 · Cited by 78
Li, X., Wang, M., Li, S., Chen, Y., Wang, M., Wu, Z., Sun, X., Yao, L., Dong, H., Song, Y., et al. (2021) · Theranostics · doi:10.7150/thno.57804 · Cited by 73
Li, D., Hou, Y., Wu, J., Chen, Y., Lu, J.-S., Di, G., Ou, Z.-L., Shen, Z., Ding, J., & Shao, Z.-M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.07.008 · Cited by 65
Circulating tumor cells in breast cancer: A tool whose time has come of age
Swaby, R. F., & Cristofanilli, M. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-43 · Cited by 65
Weng, D., Penzner, J. H., Song, B., Koido, S., Calderwood, S. K., & Gong, J. (2012) · Breast Cancer Research · doi:10.1186/bcr3102 · Cited by 65
“Breast cancer is initiated as a local disease but can also seed metastases to distant organs; indeed the spread of cancer cells from primary tumor sites to distant organs accounts for the majority of deaths in breast cancer patients [1].”
BackgroundMa, Y., Zhang, P., Wang, F., Moyer, M. P., Yang, J., Liu, Z., Peng, J.-Y., Chen, H., Zhou, Y.-K., Liu, W., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01170.x · Cited by 65
Lanier, M. H., Kim, T., & Cooper, J. A. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-08-0552 · Cited by 65
“INTRODUCTION Invasion of body tissues by metastatic tumor cells is the main cause of death in patients with cancer (Weigelt et al., 2005).”
BackgroundImpact of host genetic polymorphisms on vaccine induced antibody response
Linnik, J., & Egli, A. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1119345 · Cited by 70
Wang, F., Sun, Q., Feng, B., Xu, Z., Zhang, J., Xu, J., Lu, L., Yu, H., Wang, M., Li, Y., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600283 · Cited by 67
A TRACER 3D Co-Culture tumour model for head and neck cancer
Young, M. C., Rodenhizer, D., Dean, T., D’Arcangelo, E., Xu, B., Ailles, L., & McGuigan, A. P. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.038 · Cited by 70
Cheng, J., Holland‐Letz, T., Wallwiener, M., Surowy, H., Ćuk, K., Schott, S., Trumpp, A., Pantel, K., Sohn, C., Schneeweiß, A., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4666-5 · Cited by 69
Zhang, Y., He, W., & Zhang, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00138 · Cited by 74
Gu, P., Sun, M., Li, L., Yang, Y., Jiang, Z., Ge, Y., Wang, W., Mu, W., & Wang, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.657158 · Cited by 67
Modeling Metastatic Breast Cancer in Mice
Jonkers, J., & Derksen, P. W. B. (2007) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-007-9050-8 · Cited by 65
“Currently, depending on the guidelines used, 50 to over 80% of breast cancer patients receive adjuvant therapy, even though only 25– 40% of them will relapse and ultimately die of metastatic disease [38].”
BackgroundNeelakantan, D., Drasin, D. J., & Ford, H. L. (2014) · Cell Adhesion & Migration · doi:10.4161/19336918.2014.972761 · Cited by 69
Investigating Breast Cancer Cell Behavior Using Tissue Engineering Scaffolds
Guiro, K., Patel, S. A., Greco, S. J., Rameshwar, P., & Arinzeh, T. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118724 · Cited by 68
Alemayehu, M., Dragan, M., Pape, C., Siddiqui, I. F. S., Sacks, D. B., Guglielmo, G. M. D., Babwah, A. V., & Bhattacharya, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056174 · Cited by 70
Lehn, S., Tobin, N. P., Berglund, P., Nilsson, K., Sims, A. H., Jirström, K., Härkönen, P. L., Lamb, R., & Landberg, G. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100303 · Cited by 64
Kim, D.-H., Kim, J., Kim, E., Na, H.-K., Cha, Y.-N., Chung, J. H., & Surh, Y. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp012 · Cited by 70
Claudin 1 in Breast Cancer: New Insights
Zhou, B., Moodie, A., Blanchard, A., Leygue, E., & Myal, Y. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4121952 · Cited by 70
Rutin as A Novel c-Met Inhibitory Lead for The Control of Triple Negative Breast Malignancies
Elsayed, H. E., Ebrahim, H. Y., Mohyeldin, M. M., Siddique, A. B., Kamal, A. M., Haggag, E. G., & Sayed, K. A. E. (2017) · Nutrition and Cancer · doi:10.1080/01635581.2017.1367936 · Cited by 64
Chida, T., Miura, Y., Cabral, H., Nomoto, T., Kataoka, K., & Nishiyama, N. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.035 · Cited by 72
Fluorogenic Trp(redBODIPY) cyclopeptide targeting keratin 1 for imaging of aggressive carcinomas
Subirós‐Funosas, R., Ho, V. C. L., Barth, N. D., Mendive‐Tapia, L., Pappalardo, M., Barril, X., Ma, R., Zhang, C., Qian, B., Sintes, M., et al. (2019) · Chemical Science · doi:10.1039/c9sc05558d · Cited by 66
Spatial Analysis of Breast Cancer Incidence in Iran
Mahdavifar, N., Pakzad, R., Ghoncheh, M., Pakzad, I., Moudi, A., & Salehiniya, H. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.s3.59 · Cited by 63
Tan, H., Gan, F., Wu, Y., Zhou, J., Tian, J., Lin, Y., & Wang, M. (2019) · Academic Radiology · doi:10.1016/j.acra.2019.11.004 · Cited by 63
Halim, H., Chunhacha, P., Suwanborirux, K., & Pithi Chanvorachote, B. (2011) · PubMed · Cited by 63
AiErken, N., Shi, H.-J., Zhou, Y., Shao, N., Zhang, J., Shi, Y., Yuan, Z.-Y., & Lin, Y. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.20868 · Cited by 67
YAP promotes breast cancer metastasis by repressing growth differentiation factor-15
Wang, T., Mao, B., Cheng, C., Zou, Z., Gao, J., Yang, Y., Lei, T., Qi, X., Yuan, Z., Xu, W., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.02.020 · Cited by 68
Beyond Capture: Circulating Tumor Cell Release and Single‐Cell Analysis
Wu, L., Xu, X., Sharma, B., Wang, W., Qu, X., Zhu, L., Zhang, H., Song, Y., & Yang, C. (2019) · Small Methods · doi:10.1002/smtd.201800544 · Cited by 61
A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness
Pegoraro, S., Ros, G., Ciani, Y., Sgarra, R., Piazza, S., & Manfioletti, G. (2015) · Oncotarget · doi:10.18632/oncotarget.4236 · Cited by 62
“A critical step in the clinical outcome of breast cancer is the metastatic spread of cancer cells [1].”
Zevon, M., Ganapathy, V., Kantamneni, H., Mingozzi, M., Kim, P., Adler, D., Sheng, Y., Tan, M. C., Pierce, M., Riman, R. E., et al. (2015) · Small · doi:10.1002/smll.201502202 · Cited by 62
Inhibition of Filamin-A Reduces Cancer Metastatic Potential
Jiang, X., Yue, J., Lu, H., Campbell, N., Yang, Q., Lan, S., Haffty, B. G., Yuan, C., & Shen, Z. (2013) · International Journal of Biological Sciences · doi:10.7150/ijbs.5577 · Cited by 62
MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met
Gao, Y., Zeng, F., Wu, J., Li, H., Fan, J., Mai, L., Zhang, J., Ma, D., Li, Y., & Song, F. (2014) · Tumor Biology · doi:10.1007/s13277-014-2917-6 · Cited by 62
Dou, X., Liang, Y., Lin, H., Wei, X., Zhang, Y., Bai, J., Chen, C., Chen, M., Du, C., Li, Y., et al. (2017) · Theranostics · doi:10.7150/thno.19989 · Cited by 72
“The majority of breast cancer deaths result from metastasis at distant sites [1].”
BackgroundUSP11 Enhances TGFβ-Induced Epithelial–Mesenchymal Plasticity and Human Breast Cancer Metastasis
Garcia, D. A., Baek, C., Estrada, M. V., Tysl, T., Bennett, E. J., Yang, J., & Chang, J. T. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0723 · Cited by 67
Botsikas, D., Bagetakos, I., Picarra, M., Barisits, A. C. D. C. A., Boudabbous, S., Montet, X., Lam, G. T., Mainta, I., Kalovidouri, A., & Becker, M. (2018) · European Radiology · doi:10.1007/s00330-018-5720-8 · Cited by 62
Torka, R., Thuma, F., Herzog, V., & Kirfel, G. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.08.025 · Cited by 72
Nourmohammadi, S., Aung, T. N., Cui, J., Pei, J. V., Ieso, M. L. D., Harata‐Lee, Y., Qu, Z., Adelson, D. L., & Yool, A. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00314 · Cited by 61
“4 Introduction 75 Cancer progression results from uncontrolled migration of cells away from the primary 76 tumor, intravasation into lymphatic or vascular circulation, invasion into secondary tissues 77 and the formation of metastasized tumors (1, 2) which are the main cause of cancer-related 78 deaths (3-5).”
BackgroundPRMT2 and RORγ Expression Are Associated With Breast Cancer Survival Outcomes
Oh, T. G., Bailey, P. J., Dray, E. V., Smith, A. G., Goode, J. M., Eriksson, N. A., Funder, J. W., Fuller, P. J., Simpson, E. R., Tilley, W. D., et al. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1403 · Cited by 66
Blood Peptidome-Degradome Profile of Breast Cancer
Shen, Y., Tolić, N., Liu, T., Zhao, R., Petritis, B. O., Gritsenko, M. A., Camp, D., Moore, R., Purvine, S. O., Esteva, F. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013133 · Cited by 70
The emerging molecular machinery and therapeutic targets of metastasis
Sun, Y., & Ma, L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.001 · Cited by 63
Faraj, A. A., Shaik, A. S., Sayed, B. A., Halwani, R., & Jammaz, I. A. (2015) · Nanomedicine · doi:10.2217/nnm.15.182 · Cited by 61
Stewart, R. L., Carpenter, B. L., Piecoro, D. W., Knifley, T., Liu, L., Wang, C., Weiss, H. L., Gal, T. S., Durbin, E. B., Arnold, S. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8969 · Cited by 63
“The majority of patients with advanced NSCLC die within 18 months of diagnosis, usually as a result of metastatic disease [21, 22].”
Chen, Y., Lee, Y., Huang, C., & Chang, L. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.007 · Cited by 61
Advanced drug delivery system with nanomaterials for personalised medicine to treat breast cancer
Han, H. J., Ekweremadu, C., & Patel, N. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.05.024 · Cited by 62
Biological role of NHERF1 protein expression in breast cancer
Mangia, A., Chiriatti, A., Bellizzi, A., Malfettone, A., Stea, B., Zito, F. A., Reshkin, S. J., Simone, G., & Paradiso, A. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03424.x · Cited by 63
A superstatistical model of metastasis and cancer survival
Chen, L. L., & Beck, C. (2008) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2008.01.116 · Cited by 61
Bechnak, L., Khalil, C., Kurdi, R. E., Khnayzer, R. S., & Patra, D. (2020) · Photochemical & Photobiological Sciences · doi:10.1039/d0pp00032a · Cited by 61
Liang, H., Du, Y., Zhu, C., Zhang, Z., Liao, G., Liu, L., & Chen, Y. (2023) · ACS Nano · doi:10.1021/acsnano.2c11280 · Cited by 61
Metadata
- Authors
- Weigelt, B., Peterse, J. L., & van't Veer, L. J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- ORCID
- Weigelt, Britta
- Venue
- Nature Reviews Cancer
- Published
- 2005-08-01
- Volume
- 5
- Issue
- 8
- Pages
- 591-602
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2004280628
- Semantic Scholar
- 3bd1490d7b6c8daa59bd35260c6c71e39d3d62fa
- Cited by
- 2,232
- References
- 112
- Citations by year
- 2026: 34 · 2025: 69 · 2024: 90 · 2023: 111 · 2022: 139 · 2021: 154 · 2020: 159 · 2019: 147 · 2018: 140 · 2017: 191 · 2016: 162 · 2015: 152 · 2014: 121 · 2013: 104 · 2012: 88
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- breast cancer, metastasis, prognostic factors, metastatic potential, lymph node metastasis, distant metastasis, carcinogenesis, DNA microarrays, systemic disease, metastasis model
- MeSH terms
- Breast Neoplasms, Female, Humans, Neoplasm Metastasis, Biomarkers, Tumor, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.